BOTALYS Raises €6.6 Million Series B to Scale Sustainable Indoor Farming of High-Value Botanicals
Belgian ag‑biotech and biomimetic indoor farming specialist BOTALYS has made headlines with a major Series B funding round of €6.6 million that will support its global growth, expand its proprietary hydroponic platform and accelerate commercial deployment of ultra‑premium botanical ingredients for the nutraceutical, cosmetic and pharmaceutical sectors.
Founded in 2011 and based in Ath, Belgium, BOTALYS pioneered a vertical farming technology capable of cultivating rare medicinal plants in controlled environments that replicate wild biotopes, producing botanicals with unparalleled purity, potency and consistency. The company’s approach enables cultivation of plants such as Panax ginseng—whose roots can yield 10–15 times more valuable ginsenosides than field‑grown counterparts in a fraction of the time—while preserving biodiversity and minimizing environmental impact.
The €6.6 million Series B round was led by ALIAD, the venture capital arm of Air Liquide, which invests in innovative technologies aligned with energy transition and health strategies. ALIAD’s participation not only provides critical growth capital but also opens doors to commercial and technological collaboration with Seppic, a subsidiary of Air Liquide Healthcare and a global player in ingredient development for cosmetics, nutraceuticals, pharmaceuticals and industrial applications.
Joining ALIAD in the round was impact‑oriented agritech investor Yield Lab Europe, which focuses on early‑stage ventures advancing sustainable agricultural and food systems. Yield Lab Europe’s involvement brings both capital and sector expertise to support BOTALYS’ mission of reshaping how high‑value botanicals are cultivated and supplied.
Historic backers also participated, including Belgian public and private investors such as VIVES II – Louvain Technology Fund, SRIW and Hoccinvest, alongside a group of prominent family offices that have supported BOTALYS’ growth trajectory over time. These investors originally backed earlier stages of development, which included financing construction and commissioning of the company’s advanced 40,000 square‑foot vertical farming facility.
The fresh capital injection will enable BOTALYS to scale its hydroponic precision farming technology beyond ginseng to additional rare medicinal plants that are difficult or unsustainable to cultivate using traditional methods. This expansion is expected to broaden the company’s product portfolio of botanicals used in dietary supplements, functional foods, cosmeceuticals and pharmaceutical precursors, increasing its appeal to global customers seeking traceable and sustainable bioactive ingredients.
In addition to product development, the investment will accelerate BOTALYS’ international commercial deployment, particularly into the American and Asian markets, where demand for high‑purity, sustainable botanical ingredients continues to grow. The company sees this funding as a pivotal step toward establishing itself as a global leader in precision agriculture of rare medicinal plants.
Co‑founder and CEO Pierre‑Antoine Mariage has articulated BOTALYS’ vision of setting new standards in botanical quality and sustainability, emphasizing that the company’s technology produces ingredients that meet both ultra‑pure quality and environmental criteria demanded by modern consumers and manufacturers alike. Its cultivation platform is designed to offer traceability, consistency and efficiency that are difficult to achieve with wild‑harvested or conventionally farmed plants.
BOTALYS’ platform has attracted strategic industry interest beyond pure investment: in recent years the company has entered collaborations with partners such as Haleon, a global consumer healthcare company, to jointly develop high‑performance botanical ingredients suited to wellness and health applications, demonstrating the broader commercial relevance of its cultivated botanicals.
By leveraging indoor vertical farming and controlled environment agriculture, BOTALYS aims to mitigate supply‑chain constraints common in natural botanical sourcing, such as seasonal availability, wild‑population depletion and variability in phytochemical composition. Its model provides an alternative that enhances sustainability while meeting stringent quality expectations for products destined for nutraceutical and therapeutic use.
The Series B funding round underscores investor confidence not only in BOTALYS’ proprietary technology but also in its potential to reshape the global market for bioactive botanical ingredients—a segment driven by rising consumer interest in natural health, wellness and clean cosmetic products. As the company scales, it plans to deepen its research capabilities and extend the range of plants cultivated using its biomimetic indoor farming platform.
With its expanded capital base and strengthened investor roster, BOTALYS is poised to continue its transition from a pioneering vertical farm to a globally recognised supplier of ultra‑premium botanicals, combining sustainable innovation with commercial scale.
